Xtant Medical Holdings, Inc. (XTNT): Price and Financial Metrics
GET POWR RATINGS... FREE!
XTNT Stock Summary
- With a market capitalization of $65,195,633, XTANT MEDICAL HOLDINGS INC has a greater market value than only 15.76% of US stocks.
- Of note is the ratio of XTANT MEDICAL HOLDINGS INC's sales and general administrative expense to its total operating expenses; 82.93% of US stocks have a lower such ratio.
- Over the past twelve months, XTNT has reported earnings growth of 308.11%, putting it ahead of 94.56% of US stocks in our set.
- If you're looking for stocks that are quantitatively similar to XTANT MEDICAL HOLDINGS INC, a group of peers worth examining would be PESI, NVFY, PLXP, SNOA, and CURI.
- Visit XTNT's SEC page to see the company's official filings. To visit the company's web site, go to www.xtantmedical.com.
XTNT Valuation Summary
- In comparison to the median Healthcare stock, XTNT's price/earnings ratio is 137.5% lower, now standing at -8.7.
- XTNT's price/sales ratio has moved down 25.4 over the prior 151 months.
Below are key valuation metrics over time for XTNT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| XTNT | 2022-11-25 | 1.3 | 2.3 | -8.7 | -10.3 |
| XTNT | 2022-11-23 | 1.3 | 2.2 | -8.4 | -9.9 |
| XTNT | 2022-11-22 | 1.2 | 2.1 | -7.9 | -9.3 |
| XTNT | 2022-11-21 | 1.2 | 2.1 | -8.1 | -9.6 |
| XTNT | 2022-11-18 | 1.3 | 2.2 | -8.5 | -10.0 |
| XTNT | 2022-11-17 | 1.2 | 2.1 | -7.9 | -9.3 |
XTNT Growth Metrics
- The 2 year net cashflow from operations growth rate now stands at 127.56%.
- Its 3 year net cashflow from operations growth rate is now at -49.39%.
- Its 3 year net income to common stockholders growth rate is now at 89.6%.
The table below shows XTNT's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 56.668 | -2.63 | -8.559 |
| 2022-06-30 | 55.983 | -1.492 | -8.01 |
| 2022-03-31 | 55.681 | 0.742 | -7.033 |
| 2021-12-31 | 55.263 | 0.439 | -4.849 |
| 2021-09-30 | 55.309 | 0.932 | -3.272 |
| 2021-06-30 | 55.548 | 1.787 | -2.828 |
XTNT Stock Price Chart Interactive Chart >
XTNT Price/Volume Stats
| Current price | $0.60 | 52-week high | $0.92 |
| Prev. close | $0.59 | 52-week low | $0.43 |
| Day low | $0.57 | Volume | 16,000 |
| Day high | $0.61 | Avg. volume | 49,764 |
| 50-day MA | $0.66 | Dividend yield | N/A |
| 200-day MA | $0.61 | Market Cap | 65.03M |
Xtant Medical Holdings, Inc. (XTNT) Company Bio
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and devices in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as could be used in conjunction with a hardware plate system. The company is based in Montana.
Latest XTNT News From Around the Web
Below are the latest news stories about XTANT MEDICAL HOLDINGS INC that investors may wish to consider to help them evaluate XTNT as an investment opportunity.
Xtant Medical Honors Donor Hero Asante Contreras on the Donate Life Rose Parade® FloatAsante Contreras, Donor Hero Asante Contreras, Donor Hero Company Sponsors Donate Life Float at Rose Parade for the Ninth Year BELGRADE, Mont., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, honors Asante Contreras, a donor hero, as part of its continued sponsorship of the 2023 Donate Life Float at the Rose Parade in Pasadena on Monday, January 2, 2023. |
Xtant Medical Announces Third Quarter 2022 Financial ResultsBELGRADE, Mont., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2022. “I am pleased that third quarter revenues increased by 5% year-over-year, led by 12% growth in our biologics business. Driven by the successful launches of our OsteoFactor™ and OsteoVive® Plus biol |
Xtant Medical to Issue Third Quarter 2022 Financial Results on November 3, 2022BELGRADE, Mont., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2022, before the open of the financial markets on Thursday, November 3, 2022. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a confere |
Xtant Medical Announces Closing of Second Tranche of $9.75 Million Private InvestmentBELGRADE, Mont., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the closing of the second and final tranche of its previously announced private placement with a select group of accredited investors led by Stavros Vizirgianakis. As previously announced, at the first closing the Company sold approximately 14.1 million shares of common stock |
Xtant Medical Announces Closing of First Tranche of $9.75 Million Private InvestmentBELGRADE, Mont., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the closing of the first tranche of its previously announced private placement with a select group of accredited investors led by Stavros Vizirgianakis. The Company sold approximately 14.1 million shares of common stock and warrants to purchase approximately 3.5 million share |
XTNT Price Returns
| 1-mo | -8.84% |
| 3-mo | N/A |
| 6-mo | -0.50% |
| 1-year | -14.74% |
| 3-year | -63.75% |
| 5-year | -91.97% |
| YTD | 7.14% |
| 2021 | -53.18% |
| 2020 | -25.24% |
| 2019 | -0.62% |
| 2018 | -76.46% |
| 2017 | 3.64% |
Continue Researching XTNT
Want to see what other sources are saying about Xtant Medical Holdings Inc's financials and stock price? Try the links below:Xtant Medical Holdings Inc (XTNT) Stock Price | Nasdaq
Xtant Medical Holdings Inc (XTNT) Stock Quote, History and News - Yahoo Finance
Xtant Medical Holdings Inc (XTNT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...